ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

Currency in EUR. All numbers in thousands
Total Revenue1,8374,8588,819
Cost of Revenue---
Gross Profit1,8374,8588,819
Operating Expenses
Research Development119,58869,63744,026
Selling General and Administrative16,18912,13410,228
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-133,940-76,913-45,435
Income from Continuing Operations
Total Other Income/Expenses Net1,1087,70012,002
Earnings Before Interest and Taxes-132,832-69,213-33,434
Interest Expense16,5183,2823,038
Income Before Tax-149,350-72,495-36,472
Income Tax Expense-573-239-708
Minority Interest---
Net Income From Continuing Ops-148,777-72,256-35,763
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-148,777-72,256-35,763
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-148,777-72,256-35,763